



NEWS RELEASE

## Castle Biosciences Named in Inc.'s First-Annual Best-Led Companies

11/17/2021

Inaugural roundup of companies includes top 250 that proved management excellence across the middle market

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to transform disease management and improve patient outcomes, today announced that it has been named in Inc.'s first-annual Best-Led Companies list, a select, data-driven list of the very strongest U.S. firms with revenue of \$50 million to \$2 billion.

"This inaugural list of companies represents the remarkable mid-sized companies, both public and private, often founder-led, that are at the vanguard of reinventing American business," says Scott Omelianuk, editor-in-chief of Inc. magazine. "With their leadership, all business will benefit from an exciting, competitive future full of possibilities."

"At Castle, our commitment to improving patients' lives through innovative diagnostics is what drives us forward; it is a passion that has ignited a strong purpose in our business since our founding," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Being ranked in Inc.'s inaugural Best-Led Companies list is an honor and affirms that we have built our business on a solid foundation that we believe will drive sustainable growth for years to come."

The list recognizes 250 companies that are agile enough to maneuver but also big enough to have a broad impact. These companies employ 35 million people, about one of four U.S. workers. All 250 have a successful track record with leadership teams that spur solid performance, create value, penetrate markets, engage with customers and more.

Applicants were analyzed via an algorithm that identified the strongest companies based on accomplishments in four key areas: performance and value creation; market penetration and customer engagement; talent; and leadership team.

To compile the list, Inc. evaluated private and public U.S.-based companies with a 2020 revenue of \$50 million to \$2 billion or a valuation of \$50 million to \$10 billion using a proprietary 14-point measure of management excellence generated with input from partners at Pitchbook and Shango Labs.

To see the complete list, go to: <https://www.inc.com/best-led-companies>.

## About Inc.

The world's most trusted business-media brand, Inc., offers entrepreneurs the knowledge, tools, connections, and community they need to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across various channels, including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 allows the founders of the best businesses to engage with an exclusive community of their peers and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit [www.inc.com](http://www.inc.com).

## About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx® -CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (myPath® Melanoma, DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information about Castle's gene expression profile tests, visit [www.CastleTestInfo.com](http://www.CastleTestInfo.com).

Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix.

For more information, visit [www.CastleBiosciences.com](http://www.CastleBiosciences.com).

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

## Forward-Looking Statements

The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our ability to drive sustainable growth for years to come. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business and the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended Sept. 30, 2021, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

### Investor Contact:

Camilla Zuckero

832-835-5158

[czuckero@castlebiosciences.com](mailto:czuckero@castlebiosciences.com)

### Media Contact:

Allison Marshall

[amarshall@castlebiosciences.com](mailto:amarshall@castlebiosciences.com)

Source: Castle Biosciences, Inc.